Drug Profile
Balapiravir
Alternative Names: R-1626; RO-4588161Latest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator Novartis
- Developer Roche
- Class Antivirals; Pyrimidine nucleosides; Small molecules
- Mechanism of Action Hepatitis C virus NS 5 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Hepatitis C
Most Recent Events
- 21 Oct 2008 Discontinued - Phase-II for Hepatitis C in Australia (PO)
- 21 Oct 2008 Discontinued - Phase-II for Hepatitis C in Austria (PO)
- 21 Oct 2008 Discontinued - Phase-II for Hepatitis C in Canada (PO)